Literature DB >> 29182438

High numbers of myeloid derived suppressor cells in peripheral blood and ascitic fluid of cirrhotic and HCC patients.

Nadia Elwan1, Mohamed Labib Salem2, Abdelrahman Kobtan1, Ferial El-Kalla1, Loai Mansour1, Mohamed Yousef1, Ashraf Al-Sabbagh3, Abdel-Aziz A Zidan4, Sherief Abd-Elsalam1.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) is the 3rd most common cause of cancer-related death worldwide. It has evolved different immune escape mechanisms, which might include emergence of lymphoid and myeloid regulatory cells. Aim of this work: To determine the numbers of Myeloid-derived suppressor cells (MDSCs) in peripheral blood and ascitic fluid in cirrhosis and HCC and their relation to IFN-γ and α-fetoprotein (α-FP). PATIENTS AND METHODS: Sixty individuals were enrolled in this study; forty cirrhotic patients with ascites; twenty without HCC (Group I), and twenty with HCC (group II) as well as twenty healthy individuals as a control group (group III). The phenotype and numbers of MDSCs were analyzed in peripheral blood of all the individuals and ascitic fluid of the patients using flow cytometry. Intracellular IFN-γ and serum alfa-fetoprotein were measured.
RESULTS: Significant increases in the relative and the mean number of peripheral blood MDSCs were found in the cirrhosis and HCC groups than in the control group, with the HCC group showing the highest number. MDSC count was negatively correlated with IFN-γ levels, while α-FP was positively correlated with MDSC% in the HCC group. MDSC count was low in ascitic fluid of both HCC and cirrhosis groups with no significant difference between the 2 groups.
CONCLUSION: A high frequency of MDSCs was detected in the peripheral blood of cirrhotic and HCC patients, indicating presence of immunosuppressive arms. These cells could be targeted to develop a new effective immunotherapy or an adjuvant to current therapies.

Entities:  

Keywords:  HCC; Hepatocellular carcinoma; MDSCs; immunotherapy; myeloid-derived suppressor cells

Mesh:

Substances:

Year:  2017        PMID: 29182438     DOI: 10.1080/08820139.2017.1407787

Source DB:  PubMed          Journal:  Immunol Invest        ISSN: 0882-0139            Impact factor:   3.657


  9 in total

Review 1.  Neutrophils as potential therapeutic targets in hepatocellular carcinoma.

Authors:  Daniel Geh; Jack Leslie; Rob Rumney; Helen L Reeves; Thomas G Bird; Derek A Mann
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-01-12       Impact factor: 46.802

2.  Granulocyte-Macrophage Colony-Stimulating Factor Modulates Myeloid-Derived Suppressor Cells and Treg Activity in Decompensated Cirrhotic Patients With Sepsis.

Authors:  Rashi Sehgal; Rakhi Maiwall; Vijayaraghavan Rajan; Mojahidul Islam; Sukriti Baweja; Navkiran Kaur; Guresh Kumar; Gayatri Ramakrishna; Shiv K Sarin; Nirupma Trehanpati
Journal:  Front Immunol       Date:  2022-06-03       Impact factor: 8.786

Review 3.  Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors.

Authors:  Liangliang Xu; Chang Zou; Shanshan Zhang; Timothy Shun Man Chu; Yan Zhang; Weiwei Chen; Caining Zhao; Li Yang; Zhiyuan Xu; Shaowei Dong; Hao Yu; Bo Li; Xinyuan Guan; Yuzhu Hou; Feng-Ming Kong
Journal:  J Hematol Oncol       Date:  2022-07-07       Impact factor: 23.168

4.  TIPS Is Not Associated with a Higher Risk of Developing HCC in Cirrhotic Patients: A Systematic Review and Meta-analysis.

Authors:  Bin Chen; Long Pang; Hao-Bin Chen; Dong-Bo Wu; Yong-Hong Wang; En-Qiang Chen
Journal:  J Clin Transl Hepatol       Date:  2019-06-14

Review 5.  Myeloid-derived suppressor cells in gastrointestinal cancers: A systemic review.

Authors:  Maham Farshidpour; Monjur Ahmed; Shilpa Junna; Juanita L Merchant
Journal:  World J Gastrointest Oncol       Date:  2021-01-15

6.  Myeloid-Derived Suppressor Cells in Patients With Acute Pancreatitis With Increased Inhibitory Function.

Authors:  Lili Ding; Minjie Wan; Dong Wang; Huiru Cao; Haijiao Wang; Pujun Gao
Journal:  Front Immunol       Date:  2022-07-14       Impact factor: 8.786

7.  The prognostic value of myeloid derived suppressor cell level in hepatocellular carcinoma: A systematic review and meta-analysis.

Authors:  Xinyu Zhang; Xin Fu; Tianyu Li; Huimin Yan
Journal:  PLoS One       Date:  2019-12-02       Impact factor: 3.240

8.  Serum Dickopff 1 as a Novel Biomarker in Hepatocellular Carcinoma Diagnosis and Follow Up After Ablative Therapy.

Authors:  Yehia Sadek Younis; Hatem Samir Alegaily; Waleed Elagawy; Atteyat Aboelmaged Semeya; Yousry Esam-Eldin Abo-Amer; Mohamed El-Abgeegy; Sahar Mohamed Mostafa; Heba Fadl Elsergany; Sherief Abd-Elsalam
Journal:  Cancer Manag Res       Date:  2019-12-17       Impact factor: 3.989

Review 9.  The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion.

Authors:  Paola De Cicco; Giuseppe Ercolano; Angela Ianaro
Journal:  Front Immunol       Date:  2020-07-30       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.